★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★
VOL. XCIV, NO. 247
Stock Profile
Amgen Inc. (AMGN) Moat Analysis
Amgen Inc.
AMGN · Nasdaq Stock Market
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Request update
Spot something outdated? Send a quick note and source so we can refresh this profile.
Overview
Amgen Inc. is a global biopharmaceutical company with economically distinct businesses in core innovative medicines, a rare-disease portfolio, and biosimilars. Q1 2026 revenue mix was approximately 76% core, 14% rare disease and 10% biosimilars; total revenue grew 6%, while product volume growth was partly offset by lower net prices and inventory. The defensible mechanisms are product-specific patents/exclusivity and the difficulty of scaling and validating biologics manufacturing. Rare-disease assets can enjoy concentrated positions, but first-to-market status alone is not treated as a moat and competition and payer pushback remain important. Biosimilars are structurally price-led, with manufacturing know-how and reliable supply more relevant than brand. TEPEZZA subcutaneous Phase 3 results were positive, while Prolia sales fell 34% as biosimilar competition intensified.
Primary segment
Core Innovative Medicines
Market structure
Competitive
Market share
—
HHI: —
Coverage
3 segments · 6 tags
Updated 2026-07-12
Segments
Core Innovative Medicines
Branded biopharmaceutical therapies for common diseases (bone health, inflammation, oncology, cardiovascular and other specialty areas)
Revenue
76.1%
Structure
Competitive
Pricing
moderate
Share
—
Peers
Rare Disease Portfolio (Horizon + others)
Rare disease and ultra-rare specialty therapeutics (e.g., thyroid eye disease, chronic refractory gout, NMOSD, ANCA-associated vasculitis)
Revenue
14.2%
Structure
Quasi-Monopoly
Pricing
strong
Share
—
Peers
Biosimilars
Biosimilar biologic drugs (e.g., adalimumab, bevacizumab and other reference biologics)
Revenue
9.7%
Structure
Oligopoly
Pricing
weak
Share
—
Peers
Moat Claims
Core Innovative Medicines
Branded biopharmaceutical therapies for common diseases (bone health, inflammation, oncology, cardiovascular and other specialty areas)
Q1 2026 revenue share is the residual after rare disease and biosimilars: $6.562B / $8.618B total revenue. The residual includes $400M of collaboration and royalty revenue. Source: Amgen Q1 2026 Form 10-Q and product-sales detail.
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Key products are protected by patent portfolios and (where applicable) regulatory exclusivity; this supports premium pricing and delays direct copies until loss of exclusivity.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Patent challenges and unfavorable litigation outcomes
- Accelerated net price declines after biosimilar/generic entry
- Regulatory or legislative changes that compress exclusivity (e.g., price controls)
Leading indicators
- Patent expiry calendar and major litigation milestones
- FDA/EMA approvals for competing biosimilars/generics
- Net selling price trend (gross-to-net) for mature brands
Counterarguments
- Many therapeutic areas are crowded with alternative mechanisms, limiting pricing even during exclusivity
- Some revenues are concentrated in mature brands already facing net price declines
Capex Knowhow Scale
Supply
Capex Knowhow Scale
Strength
Durability
Confidence
Evidence
Large-scale biologics manufacturing requires substantial capital, specialized know-how, validation, and quality systems, which are difficult to replicate quickly.
Capex Knowhow Scale moat: definition, examples, and stocks
Erosion risks
- Manufacturing disruptions, quality issues, or supply interruptions
- Technology shifts (e.g., novel modalities) that reduce relevance of existing capacity
- Greater outsourcing/CMO availability lowering entry barriers
Leading indicators
- Batch success/yield trends and supply reliability
- Capacity expansion milestones and capex cadence
- Regulatory inspection outcomes across manufacturing network
Counterarguments
- Other large biopharma firms also possess global manufacturing scale
- Some therapies can be outsourced to specialized CMOs, reducing the advantage
Rare Disease Portfolio (Horizon + others)
Rare disease and ultra-rare specialty therapeutics (e.g., thyroid eye disease, chronic refractory gout, NMOSD, ANCA-associated vasculitis)
Q1 2026 rare-disease revenue was approximately $1.221B / $8.618B total revenue, summing TEPEZZA ($490M), KRYSTEXXA ($255M), UPLIZNA ($262M), TAVNEOS ($119M), Ultra-Rare products ($98M), and the reported negative $3M rare-disease component of other products.
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Patent coverage and exclusivity help defend high-value specialty indications, but durability depends on patent strength, enforcement, and eventual competitive innovation.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Patent challenges and earlier-than-expected loss of exclusivity
- Off-label substitution or new standards of care displacing branded therapy
- Safety or access controversies reducing uptake
Leading indicators
- Patent litigation filings/outcomes for key assets
- Pipeline disclosures from competitors in the same indications
- Net price and patient access trends in specialty channels
Counterarguments
- Rare disease markets can attract targeted competition due to high pricing and concentrated prescriber base
Biosimilars
Biosimilar biologic drugs (e.g., adalimumab, bevacizumab and other reference biologics)
Q1 2026 biosimilars revenue was approximately $835M / $8.618B total revenue: AMJEVITA/AMGEVITA $173M, PAVBLU $280M, WEZLANA/WEZENLA $47M, MVASI $150M, and $185M of other biosimilars.
Capex Knowhow Scale
Supply
Capex Knowhow Scale
Strength
Durability
Confidence
Evidence
Biosimilars require high-quality, validated biologics manufacturing and analytics; scale and know-how reduce unit costs and improve supply reliability versus smaller entrants.
Capex Knowhow Scale moat: definition, examples, and stocks
Erosion risks
- Aggressive price competition and tender dynamics compressing returns
- Improved CMO capacity lowering entry barriers
- Interchangeability and payer mandates shifting volume to lowest-price suppliers
Leading indicators
- Biosimilar ASP/price trends by molecule
- Contract wins/losses with major payers and group purchasing organizations
- Supply reliability incidents and backorders
Counterarguments
- Biosimilars often become commoditized quickly; scale does not prevent price wars
Evidence
The following table lists our outstanding material patents for the indicated product...
Shows product-by-product patent coverage and expirations that underpin exclusivity.
...new molecular entities would receive a 12 year exclusivity period in the United States...
Supports the role of regulatory exclusivities (in addition to patents) as a legal barrier.
Highly specialized knowledge... is required to transform laboratory-scale processes into reproducible commercial manufacturing processes.
Supports the expertise/capability barrier in scaling biologics manufacturing.
It can take longer than five years to build, validate and license another manufacturing plant.
Supports high time-to-replicate capacity (capex + regulatory validation).
TEPEZZA... IGF-1R antibodies... 3/3/2029.
Example of disclosed patent expirations supporting legal protection for a key rare disease product.
Showing 5 of 8 sources.
Risks & Indicators
Erosion risks
- Patent challenges and unfavorable litigation outcomes
- Accelerated net price declines after biosimilar/generic entry
- Regulatory or legislative changes that compress exclusivity (e.g., price controls)
- Manufacturing disruptions, quality issues, or supply interruptions
- Technology shifts (e.g., novel modalities) that reduce relevance of existing capacity
- Greater outsourcing/CMO availability lowering entry barriers
Leading indicators
- Patent expiry calendar and major litigation milestones
- FDA/EMA approvals for competing biosimilars/generics
- Net selling price trend (gross-to-net) for mature brands
- Batch success/yield trends and supply reliability
- Capacity expansion milestones and capex cadence
- Regulatory inspection outcomes across manufacturing network
Research AMGN elsewhere
Keep the research going
More Rankings & Systems
Quality Stocks
High quality stocks ranked by profitability, margins, free cash flow quality, durability, solvency, and accounting...
Stock rankingUndervalued Stocks
Undervalued stocks from the NA & Europe universe, ranked with a multi-measure value system and quality controls.
Stock rankingDividend Stocks
Dividend stocks ranked by payout yield, payout sustainability, dividend growth, quality, balance-sheet safety, risk...
Stock rankingDefensive Stocks
Defensive stocks ranked by low volatility, low beta, intermediate momentum, durable profitability, balance sheet...
Stock rankingMomentum Stocks
Momentum stocks ranked by total return momentum, relative momentum, trend confirmation, and risk-adjusted momentum...
Stock rankingConviction 10
A concentrated 10-stock strategy from the NA & Europe universe, ranked across quality, value, growth, momentum, and...
Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.